Vir Biotechnology 거래 VIR

VirBiotechnology 실시간 차트

상품 기초

Weekly Search
Weekly
Daily
날짜 종료 변경 변동(%) 열기 높음 낮음

VirBiotechnology news

최신 뉴스

더 보기
Frances Wang 2025 Aug 19, 16:00

Crypto market today: BTC, ETH, BNB, SOL, DOGE, ADA, LINK, HYPE, XLM

Cryptocurrencies
Noah Lee 2025 Aug 19, 00:00

India's Russia Oil Trade & US Response: An In-Depth Analysis

Canada employment data
Tommy Yap 2025 Aug 18, 21:00

Morning Note: Canada CPI in Focus; Dollar Rises; Nikkei Pauses

Morning Note Forex Stocks Economic Data Central Banks
Frances Wang 2025 Aug 18, 16:00

Crypto news today: XRP price falls to $3.01, DOGE price hovers near $0.22

Cryptocurrencies
Tommy Yap 2025 Aug 17, 21:00

Morning Note: Gold Near Lows, Yen Strengthens, Oil Extends Losses

Morning Note Oil Gold Fed JPY
Ghko B 2025 Aug 17, 16:00

Trump family-backed crypto updates: World Liberty Financial Eyes $1.5B Raise

Cryptocurrencies
Frances Wang 2025 Aug 17, 16:00

CRWV stock is trending: what’s going on with CoreWeave Inc?

Stocks
Frances Wang 2025 Aug 17, 16:00

Crypto news today: What is the current situation of the crypto market?

Cryptocurrencies

정보

스프레드

0.03

스프레드(%)

0.6912 %

레버리지

1:10

익일 이자 매수

-0.0597 %

익일 이자 매도

-0.0292 %

통화

USD

거래 시간

시장 폐장

수요일

13:31 - 19:59

월요일

13:31-19:59

화요일

13:31-19:59

목요일

13:31-19:59

금요일

13:31-19:59

분석 및 통계

열기

---

이전 종가

---

52주 최고/최저

--- – ---

시가총액

622343680

발행 주식 수

138916000

수익 날짜 (다음)

0000-00-00

배당수익률

배당락일

예상 연간 배당금

0

예상 연간 배당수익률

0

EPS

-4.01

이 상품에 대해 자세히 알아보기

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

latest_education_articles

더 보기
Trustpilot